Sign inJoin
Company / Finance

Regeneron Pharmaceuticals, Inc.

REGN · NASDAQ

Regeneron reported $14.34 billion of 2025 revenue and $3.61 billion of Q1 2026 revenue. The thesis turns on EYLEA franchise durability, Dupixent economics, pipeline conversion, cash generation and patent/regulatory risk.

FollowAdd to WatchlistAsk Question
NASDAQREGNCoverage BootstrapRegeneron Pharmaceuticals, Inc.
Latest ReportMay 20, 2026Regeneron: the blockbuster biotech that still has to outrun concentration riskView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->
Company filters1 of 1 reports match
Clear filters
Selected tags
Nasdaq
Clear tags
Latest Thesis

Regeneron: the blockbuster biotech that still has to outrun concentration risk

Regeneron reported $14.34 billion of 2025 revenue and $3.61 billion of Q1 2026 revenue. The thesis turns on EYLEA franchise durability, Dupixent economics, pipeline conversion, cash generation and patent/regulatory risk.

May 20, 2026Research reportSlides available
Read reportOpen slidesDiscussion (0)
Regeneron Pharmaceuticals, Inc.the blockbuster biotech that still has to outrun concentration rMay 20, 2026
Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Sign in to continue

Recent Reports

Compact report index for this company.

View all 1 reports ->
ReportTypeUpdatedReadActions
Regeneron: the blockbuster biotech that still has to outrun concentration riskRegeneron reported $14.34 billion of 2025 revenue and $3.61 billion of Q1 2026 revenue. The thesis turns on EYLEA franchise durability, Dupixent economics, pipeline conversion, cash generation and patent/regulatory risk.NASDAQMay 20, 2026Research reportReadSlides